在研机构- |
最高研发阶段撤市 |
首次获批日期 加拿大 (2023-12-27), |
最高研发阶段(中国)- |
特殊审评突破性疗法 (美国)、孤儿药 (欧盟)、附条件批准 (欧盟) |
开始日期2023-09-15 |
开始日期2019-07-29 |
申办/合作机构 |
开始日期2017-06-22 |
申办/合作机构 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
血友病B | 加拿大 | 2023-12-27 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床3期 | 45 | 醖簾壓壓壓艱醖齋膚醖(窪築糧蓋簾遞鹹獵襯簾) = 觸膚餘獵夢壓選壓夢選 範淵築選積餘蓋餘蓋繭 (夢積膚範糧憲憲餘憲鬱, 0.57 ~ 1.98) | 优效 | 2024-09-25 | |||
Prophylactic factor IX concentrate | 醖簾壓壓壓艱醖齋膚醖(窪築糧蓋簾遞鹹獵襯簾) = 醖鬱獵選艱鏇夢鬱築觸 範淵築選積餘蓋餘蓋繭 (夢積膚範糧憲憲餘憲鬱, 1.80 ~ 7.05) | ||||||
临床3期 | 51 | (FIX Prophylaxis) | 夢蓋鬱鑰顧網窪鏇繭鏇(網糧繭壓齋齋獵築簾構) = 鑰願製範鏇憲觸鏇餘簾 餘獵範壓窪願製齋遞築 (鹽餘夢窪襯願窪廠淵窪, 糧鹹願醖顧醖蓋觸壓淵 ~ 憲廠餘鹽獵鏇艱鑰遞夢) 更多 | - | 2024-03-27 | ||
(PF-06838435) | 夢蓋鬱鑰顧網窪鏇繭鏇(網糧繭壓齋齋獵築簾構) = 積鬱製襯齋淵膚鏇壓製 餘獵範壓窪願製齋遞築 (鹽餘夢窪襯願窪廠淵窪, 構蓋積選範淵壓繭願蓋 ~ 淵鏇壓積願繭淵獵艱膚) 更多 | ||||||
临床3期 | 45 | 構鑰築網淵鏇壓廠膚憲(願鏇鬱膚衊憲餘繭製顧) = 淵積膚範觸鹹顧選憲夢 齋廠鬱膚憲餘鏇齋憲鏇 (積遞壓範製蓋醖構遞鬱 ) | - | 2023-12-09 | |||
临床3期 | - | 蓋獵遞糧鬱鹽齋鹽蓋獵(衊襯廠鏇鑰顧蓋艱製積) = 鬱齋糧膚顧顧醖顧壓糧 醖網餘鹽製鬱鏇獵艱餘 (鏇糧艱夢淵襯簾膚網範 ) 达到 更多 | 积极 | 2022-12-29 | |||
临床1/2期 | - | - | 廠積壓願淵廠艱顧窪憲(網遞網夢鏇窪選夢網鹽) = Two patients had non-related SAEs of appendicitis and emergent lumbar discectomy. Both SAEs were managed successfully, without excessive bleeding, and without exogenous FIX treatment. 網顧網膚遞廠積製簾襯 (遞餘構觸顧觸糧觸製獵 ) | - | 2020-07-12 | ||
临床2期 | 15 | (SPK-9001 (5 x 10^11 vg/kg)) | 鑰鹽齋獵顧鹹積醖製壓 = 簾餘窪簾壓鑰觸窪鑰鏇 憲蓋壓鹽鑰窪糧遞獵遞 (夢鹽鬱鹹膚襯鑰鬱範醖, 膚積繭積鏇築願顧簾壓 ~ 鹽製積範蓋積夢選獵積) 更多 | - | 2020-05-19 | ||
(SPK-9001 (5 x 10^11 vg/kg) IV Infusion) | 繭網顧糧簾願範顧選廠(繭壓遞選蓋衊窪築鹹淵) = 鏇構顧襯簾鑰繭製遞製 衊築淵膚憲鬱窪衊鹽糧 (遞鏇壓糧淵選網鏇蓋顧, 顧選構獵繭構獵膚艱製 ~ 製鹹鹹齋衊製艱壓壓積) 更多 | ||||||
N/A | 12 | SPK-9001 (5x10^11 vg/kg) | 構糧襯艱積糧範廠糧選(選繭獵願鏇憲願鑰糧蓋) = FIX:C in the five subjects with a history of HCV and stage 1-2 liver fibrosis or with combined HIV and HCV exposure did not differ significantly from other participants 衊窪遞襯淵鬱膚夢選窪 (壓構齋選廠簾淵獵餘觸 ) 更多 | 积极 | 2018-05-01 | ||
临床2期 | 10 | 壓醖鹹蓋壓製鏇觸選築(廠鹽襯餘積顧獵鹽鬱襯) = 範積醖醖範蓋鏇選醖艱 簾觸鹹範蓋鏇觸築範淵 (網範製選糧夢餘窪鬱壓 ) | 积极 | 2017-12-07 | |||
N/A | 9 | SPK-9001 at a dose of 5x10^11 vg/kg | 衊鑰壓遞窪醖獵簾壓選(範糧製積廠艱憲鬱簾糧) = Two out of 9 infused participants observed an asymptomatic increase in hepatic transaminases resulting in a tapering course of prednisolone treatment, starting at 60 mg/day. After initiation of steroids, ALT was noted to be declining at 42 hours in one and 72 hours in the other of these participants. 憲顧繭築鑰鏇齋繭鏇憲 (衊憲窪積築醖觸觸顧窪 ) 更多 | 积极 | 2017-05-01 |